IMV Inc IMVIF

RE:RE:US Volume

[alphaseeking001]

Totally agree with you... I think we have a much higher chance of success in ovarian than 5% just based on where the program is now... many of the stumbling blocks that normally knock down new therapies early on we are mostly past now.  I wonder if it's partly how this analyst keeps his good rating... in other words, set a really low bar and it's pretty easy to exceed it.  It also may be he just wanted to see both the DLBCL update and the topline Ovarian data before committing to putting his name behind a small company like IMV.  When you look at the other biotechs the WF fellow has recommendations on... they are all huge.  May just be playing it safe until its more of a guarantee?  Honestly though... as has been shown many times on this board over the years... what the heck do I know?

qwerty22 wrote: 5%?? Really?

I think they average success rate for immunoncology from the very start of a clinical program is something like 7%. 5% would suggest the data so far is overall very negative. Many new molecules will blow out from the get-go because they just have zero impact on tumors, we are passed that stage. I get success in cancer is a real challenge but I dont see where you can get 5% from.

europe10 wrote: US Volume is a must, for the stock to move up. It is a small early positive sign. That price falls back again hints at professional accumulators. Maybe .......

I was a bit confused over Wells Fargos 3$ target price. Apparently WF gives DLBCL a 20% probability for success but only 5% (!!) for Ovarian.